<DOC>
	<DOCNO>NCT03056833</DOCNO>
	<brief_summary>Investigators hypothesize concurrent ribociclib treatment chemotherapy enhance response platinum-based therapy maintenance therapy slow ovarian cancer tumor growth lead prolongation progression free survival .</brief_summary>
	<brief_title>Ribociclib ( Ribociclib ( LEE-011 ) ) With Platinum-based Chemotherapy Recurrent Platinum Sensitive Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Women ≥18 year old platinumsensitive recurrent ovarian , fallopian primary peritoneal cancer ( define recurrent disease &gt; 6 month complete last platinumbased chemotherapy ) eligible receive platinumbased doublet chemotherapy Must least 1 prior line platinumbased therapy ECOG ( Eastern Cooperative Oncology Group : Eastern Cooperative Oncology Group score system use quantify general wellbeing activity daily life ; score range 0 5 0 represent perfect health 5 represent death . ) 01 life expectancy ≥ 3 month Adequate organ function Screening ECG QTcF interval screen ≤450msec ( use Fridericia 's correction ) rest heart rate ≥ 50bpm Must able swallow ribociclib ( LEE011 ) tablet/capsule Documented disease recurrence/progression base GCIGRECIST Able provide inform consent comply study protocol Treated CNS ( Central Nervous System ) metastasis allow treatment complete ≥4 week prior enrollment CNS disease stable repeat image To start maintenance therapy , patient must meet following criterion : ANC ( Absolute Neutrophil Count ) ≥1 , hemoglobin ≥9 platelets ≥50 . Initiation maintenance therapy may delay hematologic count recovery must start within 6 week last dose carboplatin + paclitaxel patient eligible maintenance therapy . In woman childbearing potential ( menstrual cycle within last year tubal ligation surgical removal ovary and/or hysterectomy ) , two form contraception require Borderline lowmalignant potential histology Platinumresistant disease ( define progressive disease within 6 month completion chemotherapy platinum agent ) Grade 3 baseline neuropathy ( severe symptom ; interfere activity daily live ) History anaphylaxis serious allergic reaction carboplatin paclitaxel . Known hypersensitivity excipients ribociclib ( LEE011 ) Prior use CDK4/6 inhibitor Congenital long QT syndrome family history unexpected sudden cardiac death Concurrent malignancy malignancy within 3 year prior start study drug , exception adequately treat basal squamous cell carcinoma , nonmelanomatous skin cancer curatively resect cervical cancer Gastrointestinal ( GI ) function disease may significantly alter absorption study drug Patient concurrent severe and/or uncontrolled medical condition would , investigator 's judgment , cause unacceptable safety risk contraindicate patient 's participation clinical study compromise compliance protocol Clinically significant , uncontrolled heart disease and/or cardiac repolarization abnormality Use prohibit medication change alternative therapy Patient currently receive receive systemic corticosteroid ≤2 week prior start study drug , fully recover side effect treatment Patient currently receive warfarin coumadinderived anticoagulant treatment , prophylaxis otherwise . Therapy heparin , low molecular weight heparin ( LMWH ) fondaparinux allow . Participation prior investigational study within 30 day prior enrollment within 5 halflives investigational product , whichever longer Patient receive radiotherapy ≤4 week limit field radiation palliation ≤2 week prior start study drug , recover grade 1 well related side effect therapy Patient major surgery within 14 day prior start study drug recover major side effect ( tumor biopsy consider major surgery ) 18 . Patient recover toxicity relate prior anticancer therapy Grade &lt; 1 ( mild ) Patient ChildPugh score B C</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>